The shady side of dasatinib

Abstract

In this issue of Blood, Futosi and colleagues investigate the effects of the multikinase inhibitor dasatinib on mature human neutrophils, helping to explain the increased infection rate in chronic myelogenous leukemia (CML) patients resistant to or intolerant of imatinib. Through careful analysis of neutrophil function, the authors also develop a pathway for the development of kinase inhibitors as anti-inflammatory drugs.